Granules India gets USFDA nod for allergy treatment drug

October 24, 2019 Gubba Pharma In E News

Granules India said it has received approval for Fexofenadine Hydrochloride tablets. The approved product is bio-equivalent to the reference listed drug product (RLD), Allegra Allergy Tablets, 60 mg and 180 mg, of Sanofi-Aventis US LLC.
Drug firm Granules India said it has received approval from the US health regulator for Fexofenadine Hydrochloride tablets, used to treat allergy symptoms.
The approved product is bio-equivalent to the reference listed drug product (RLD), Allegra Allergy Tablets , 60 mg and 180 mg, of Sanofi-Aventis US LLC.
The US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by Granules India for Fexofenadine Hydrochloride tablets USP in the strengths of 60 mg and 180 mg (OTC), Granules said in a regulatory filing.

Source : economictimes.indiatimes

About the author

Gubba Group: